BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coughlan L, Alba R, Parker AL, Bradshaw AC, McNeish IA, Nicklin SA, Baker AH. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses. 2010;2:2290-2355. [PMID: 21994621 DOI: 10.3390/v2102290] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Gonzalez-Pastor R, Hernandez Y, Gimeno M, de Martino A, Man YKS, Hallden G, Quintanilla M, de la Fuente JM, Martin-Duque P. Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-cancer therapeutic efficacy. Acta Biomater 2021;134:593-604. [PMID: 34325075 DOI: 10.1016/j.actbio.2021.07.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ku MW, Charneau P, Majlessi L. Use of lentiviral vectors in vaccination. Expert Rev Vaccines 2021;:1-16. [PMID: 34620025 DOI: 10.1080/14760584.2021.1988854] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
3 Collins LT, Curiel DT. Synthetic Biology Approaches for Engineering Next-Generation Adenoviral Gene Therapies. ACS Nano 2021;15:13970-9. [PMID: 34415739 DOI: 10.1021/acsnano.1c04556] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kerstetter LJ, Buckley S, Bliss CM, Coughlan L. Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses. Front Immunol 2020;11:607333. [PMID: 33633727 DOI: 10.3389/fimmu.2020.607333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Innao V, Rizzo V, Allegra AG, Musolino C, Allegra A. Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs. Curr Oncol 2020;28:159-83. [PMID: 33704184 DOI: 10.3390/curroncol28010019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Rathnasinghe R, Strohmeier S, Amanat F, Gillespie VL, Krammer F, García-Sastre A, Coughlan L, Schotsaert M, Uccellini MB. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect 2020;9:2433-45. [PMID: 33073694 DOI: 10.1080/22221751.2020.1838955] [Cited by in Crossref: 40] [Cited by in F6Publishing: 70] [Article Influence: 20.0] [Reference Citation Analysis]
7 Rathnasinghe R, Strohmeier S, Amanat F, Gillespie VL, Krammer F, García-Sastre A, Coughlan L, Schotsaert M, Uccellini M. Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection. bioRxiv 2020:2020. [PMID: 32676603 DOI: 10.1101/2020.07.06.190066] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
8 Coughlan L. Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines. Front Immunol 2020;11:909. [PMID: 32508823 DOI: 10.3389/fimmu.2020.00909] [Cited by in Crossref: 26] [Cited by in F6Publishing: 47] [Article Influence: 13.0] [Reference Citation Analysis]
9 Wang Z, Liu W, Wang L, Gao P, Li Z, Wu J, Zhang H, Wu H, Kong W, Yu B, Yu X. Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia. Signal Transduct Target Ther 2020;5:40. [PMID: 32327638 DOI: 10.1038/s41392-020-0135-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother 2020;16:2389-402. [PMID: 32078405 DOI: 10.1080/21645515.2020.1723363] [Cited by in Crossref: 14] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
11 Wang NS, Maine CJ. Integrating context of tumor biology and vaccine design to shape multidimensional immunotherapies. Future Drug Discovery 2020;2:FDD25. [DOI: 10.4155/fdd-2019-0031] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Bliss CM, Parsons AJ, Nachbagauer R, Hamilton JR, Cappuccini F, Ulaszewska M, Webber JP, Clayton A, Hill AVS, Coughlan L. Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice. Mol Ther Methods Clin Dev 2020;16:108-25. [PMID: 31934599 DOI: 10.1016/j.omtm.2019.12.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
13 Sun Y, Lv X, Ding P, Wang L, Sun Y, Li S, Zhang H, Gao Z. Exploring the functions of polymers in adenovirus-mediated gene delivery: Evading immune response and redirecting tropism. Acta Biomater 2019;97:93-104. [PMID: 31386928 DOI: 10.1016/j.actbio.2019.06.059] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
14 Stella Man YK, Foster J, Carapuça E, Davies JA, Parker AL, Sosabowski J, Halldén G. Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Sci Rep 2019;9:12840. [PMID: 31492884 DOI: 10.1038/s41598-019-49150-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
15 Hong J, Yun CO. Overcoming the limitations of locally administered oncolytic virotherapy. BMC Biomed Eng 2019;1:17. [PMID: 32903299 DOI: 10.1186/s42490-019-0016-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
16 Liu Z, Tian X, Liu W, Xian Y, Chen W, Chen H, Zhou R. Development of two antigen-binding fragments to a conserved linear epitope of human adenovirus and their application in immunofluorescence. PLoS One 2019;14:e0219091. [PMID: 31242267 DOI: 10.1371/journal.pone.0219091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Zhang X, Qin J, Wang X, Guo X, Liu J, Wang X, Wu X, Lu X, Li W, Liu X. Netrin-1 improves adipose-derived stem cell proliferation, migration, and treatment effect in type 2 diabetic mice with sciatic denervation. Stem Cell Res Ther 2018;9:285. [PMID: 30359296 DOI: 10.1186/s13287-018-1020-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
18 Stepanenko AA, Chekhonin VP. A compendium of adenovirus genetic modifications for enhanced replication, oncolysis, and tumor immunosurveillance in cancer therapy. Gene 2018;679:11-8. [PMID: 30171937 DOI: 10.1016/j.gene.2018.08.069] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
19 Stepanenko AA, Chekhonin VP. Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX. Virus Res 2018;257:40-51. [PMID: 30125593 DOI: 10.1016/j.virusres.2018.08.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
20 Vujadinovic M, Vellinga J. Progress in Adenoviral Capsid-Display Vaccines. Biomedicines 2018;6:E81. [PMID: 30049954 DOI: 10.3390/biomedicines6030081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
21 Wang Z, Yu B, Wang B, Yan J, Feng X, Wang Z, Wang L, Zhang H, Wu H, Wu J, Kong W, Yu X. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route. Oncotarget 2016;7:47287-301. [PMID: 27323824 DOI: 10.18632/oncotarget.10075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
22 Uusi-Kerttula H, Davies J, Coughlan L, Hulin-Curtis S, Jones R, Hanna L, Chester JD, Parker AL. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget 2016;7:27926-37. [PMID: 27056886 DOI: 10.18632/oncotarget.8545] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
23 Zhu P, Duan A, Deng T, Lu X, Ma X, Liang S, Pang C, Liang X. Generation of buffalo mammary epithelial cells with targeted knockout of 18s rDNA by a CRISPR/Cas9 adenovirus system. Biotechnol Bioproc E 2017;22:569-76. [DOI: 10.1007/s12257-017-0094-3] [Reference Citation Analysis]
24 Liu X, Gao X, Zheng S, Wang B, Li Y, Zhao C, Muftuoglu Y, Chen S, Li Y, Yao H, Sun H, Mao Q, You C, Guo G, Wei Y. Modified nanoparticle mediated IL-12 immunogene therapy for colon cancer. Nanomedicine: Nanotechnology, Biology and Medicine 2017;13:1993-2004. [DOI: 10.1016/j.nano.2017.04.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
25 Zhang W, Ehrhardt A. Getting genetic access to natural adenovirus genomes to explore vector diversity. Virus Genes 2017;53:675-83. [PMID: 28711987 DOI: 10.1007/s11262-017-1487-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
26 Kurihara C, Nakade K, Pan J, Huang J, Wasylyk B, Obata Y. An easy method for preparation of Cre-loxP regulated fluorescent adenoviral expression vectors and its application for direct reprogramming into hepatocytes. Biotechnol Rep (Amst) 2016;12:26-32. [PMID: 28352551 DOI: 10.1016/j.btre.2016.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Ruščić J, Ambriović-ristov A, Majhen D, Kolundžija S, Barut M, Benihoud K, Krajačić M. Manipulating adenoviral vector ion-exchange chromatography: Hexon versus fiber: Liquid Chromatography. J Sep Sci 2016;39:4299-304. [DOI: 10.1002/jssc.201600829] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
28 Rojas LA, Condezo GN, Moreno R, Fajardo CA, Arias-badia M, San Martín C, Alemany R. Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery. Journal of Controlled Release 2016;237:78-88. [DOI: 10.1016/j.jconrel.2016.07.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
29 Guan M, Ma Y, Shah SR, Romano G. Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy. Oncolytic Virother 2016;5:35-43. [PMID: 27579295 DOI: 10.2147/OV.S99856] [Reference Citation Analysis]
30 Sweeney K, Halldén G. Oncolytic adenovirus-mediated therapy for prostate cancer. Oncolytic Virother 2016;5:45-57. [PMID: 27579296 DOI: 10.2147/OV.S63047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
31 Jang YO, Cho MY, Yun CO, Baik SK, Park KS, Cha SK, Chang SJ, Kim MY, Lim YL, Kwon SO. Effect of Function-Enhanced Mesenchymal Stem Cells Infected With Decorin-Expressing Adenovirus on Hepatic Fibrosis. Stem Cells Transl Med. 2016;5:1247-1256. [PMID: 27365486 DOI: 10.5966/sctm.2015-0323] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
32 Hulin-Curtis SL, Uusi-Kerttula H, Jones R, Hanna L, Chester JD, Parker AL. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer Gene Ther 2016;23:229-34. [PMID: 27229159 DOI: 10.1038/cgt.2016.22] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
33 Kim N, Duncan GA, Hanes J, Suk JS. Barriers to inhaled gene therapy of obstructive lung diseases: A review. J Control Release 2016;240:465-88. [PMID: 27196742 DOI: 10.1016/j.jconrel.2016.05.031] [Cited by in Crossref: 44] [Cited by in F6Publishing: 58] [Article Influence: 7.3] [Reference Citation Analysis]
34 Buijs PR, Verhagen JH, van Eijck CH, van den Hoogen BG. Oncolytic viruses: From bench to bedside with a focus on safety. Hum Vaccin Immunother 2015;11:1573-84. [PMID: 25996182 DOI: 10.1080/21645515.2015.1037058] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 10.2] [Reference Citation Analysis]
35 Farrow AL, Peng BJ, Gu L, Krendelchtchikov A, Matthews QL. A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors. Viruses 2016;8:78. [PMID: 26978385 DOI: 10.3390/v8030078] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
36 Lang S, Wang L, Wang Z, Zhu R, Yan J, Wang B, Wu J, Zhang H, Wu H, Zhou Y, Kong W, Yu B, Yu X. Localization of neutralization epitopes on adenovirus fiber knob from species C. J Gen Virol 2016;97:955-62. [PMID: 26801881 DOI: 10.1099/jgv.0.000410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
37 Uusi-Kerttula H, Hulin-Curtis S, Davies J, Parker AL. Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.Viruses. 2015;7:6009-6042. [PMID: 26610547 DOI: 10.3390/v7112923] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
38 Dicks MD, Spencer AJ, Coughlan L, Bauza K, Gilbert SC, Hill AV, Cottingham MG. Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. Sci Rep 2015;5:16756. [PMID: 26576856 DOI: 10.1038/srep16756] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
39 Alonso-Padilla J, Papp T, Kaján GL, Benkő M, Havenga M, Lemckert A, Harrach B, Baker AH. Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs. Mol Ther 2016;24:6-16. [PMID: 26478249 DOI: 10.1038/mt.2015.194] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 8.4] [Reference Citation Analysis]
40 Hansra S, Pujhari S, Zakhartchouk AN. Exploration of New Sites in Adenovirus Hexon for Foreign Peptides Insertion. Open Virol J 2015;9:1-6. [PMID: 26069516 DOI: 10.2174/1874357901509010001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
41 van Erp EA, Kaliberova LN, Kaliberov SA, Curiel DT. Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein. Mol Ther Oncolytics 2015;2:15001. [PMID: 27119101 DOI: 10.1038/mto.2015.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
42 Coughlan L, Mullarkey C, Gilbert S. Adenoviral vectors as novel vaccines for influenza. J Pharm Pharmacol 2015;67:382-99. [PMID: 25560474 DOI: 10.1111/jphp.12350] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
43 Uhrig-Schmidt S, Geiger M, Luippold G, Birk G, Mennerich D, Neubauer H, Grimm D, Wolfrum C, Kreuz S. Gene delivery to adipose tissue using transcriptionally targeted rAAV8 vectors. PLoS One 2014;9:e116288. [PMID: 25551639 DOI: 10.1371/journal.pone.0116288] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
44 Agirre M, Zarate J, Ojeda E, Puras G, Rojas LA, Alemany R, Pedraz JL. Delivery of an adenovirus vector plasmid by ultrapure oligochitosan based polyplexes. Int J Pharm 2015;479:312-9. [PMID: 25550211 DOI: 10.1016/j.ijpharm.2014.12.062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
45 Appaiahgari MB, Vrati S. Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opinion on Biological Therapy 2015;15:337-51. [DOI: 10.1517/14712598.2015.993374] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 8.6] [Reference Citation Analysis]
46 Jung SJ, Kasala D, Choi JW, Lee SH, Hwang JK, Kim SW, Yun CO. Safety profiles and antitumor efficacy of oncolytic adenovirus coated with bioreducible polymer in the treatment of a CAR negative tumor model. Biomacromolecules 2015;16:87-96. [PMID: 25400213 DOI: 10.1021/bm501116x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
47 Yerevanian A, Yerevanian A, Hajjar RJ. Progress in gene therapy for heart failure. J Cardiovasc Pharmacol 2014;63:95-106. [PMID: 23921315 DOI: 10.1097/FJC.0b013e3182a2e8b8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
48 Yamamoto Y, Hiraoka N, Goto N, Rin Y, Miura K, Narumi K, Uchida H, Tagawa M, Aoki K. A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues. J Control Release. 2014;192:284-293. [PMID: 25108153 DOI: 10.1016/j.jconrel.2014.07.053] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
49 Puig-saus C, Rojas LA, Laborda E, Figueras A, Alba R, Fillat C, Alemany R. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy. Gene Ther 2014;21:767-74. [DOI: 10.1038/gt.2014.52] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
50 Coughlan L, Uusi-Kerttula H, Ma J, Degg BP, Parker AL, Baker AH. Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation. Hum Gene Ther 2014;25:385-94. [PMID: 24617540 DOI: 10.1089/hum.2014.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
51 Wirth T, Ylä-Herttuala S. Gene Therapy Used in Cancer Treatment. Biomedicines 2014;2:149-62. [PMID: 28548065 DOI: 10.3390/biomedicines2020149] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
52 Piccolo P, Brunetti-Pierri N. Challenges and Prospects for Helper-Dependent Adenoviral Vector-Mediated Gene Therapy. Biomedicines 2014;2:132-48. [PMID: 28548064 DOI: 10.3390/biomedicines2020132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
53 Reetz J, Herchenröder O, Pützer BM. Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancer. Viruses 2014;6:1540-63. [PMID: 24699364 DOI: 10.3390/v6041540] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
54 Sumarheni S, Hong SS, Josserand V, Coll JL, Boulanger P, Schoehn G, Fender P. Human full-length coagulation factor X and a GLA domain-derived 40-mer polypeptide bind to different regions of the adenovirus serotype 5 hexon capsomer. Hum Gene Ther 2014;25:339-49. [PMID: 24512117 DOI: 10.1089/hum.2013.222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
55 Lopez-Gordo E, Podgorski II, Downes N, Alemany R. Circumventing antivector immunity: potential use of nonhuman adenoviral vectors. Hum Gene Ther 2014;25:285-300. [PMID: 24499174 DOI: 10.1089/hum.2013.228] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
56 Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood. 2014;123:2605-2613. [PMID: 24632711 DOI: 10.1182/blood-2013-09-526277] [Cited by in Crossref: 114] [Cited by in F6Publishing: 115] [Article Influence: 14.3] [Reference Citation Analysis]
57 Alemany R. Oncolytic Adenoviruses in Cancer Treatment. Biomedicines 2014;2:36-49. [PMID: 28548059 DOI: 10.3390/biomedicines2010036] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
58 Baker AH, Nicklin SA, Shayakhmetov DM. FX and host defense evasion tactics by adenovirus. Mol Ther 2013;21:1109-11. [PMID: 23728252 DOI: 10.1038/mt.2013.100] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
59 Yamamoto Y, Goto N, Miura K, Narumi K, Ohnami S, Uchida H, Miura Y, Yamamoto M, Aoki K. Development of a novel efficient method to construct an adenovirus library displaying random peptides on the fiber knob. Mol Pharm 2014;11:1069-74. [PMID: 24380399 DOI: 10.1021/mp4005854] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
60 Miest TS, Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 2014;12:23-34. [PMID: 24292552 DOI: 10.1038/nrmicro3140] [Cited by in Crossref: 169] [Cited by in F6Publishing: 165] [Article Influence: 18.8] [Reference Citation Analysis]
61 Christianson HC, Belting M. Heparan sulfate proteoglycan as a cell-surface endocytosis receptor. Matrix Biol 2014;35:51-5. [PMID: 24145152 DOI: 10.1016/j.matbio.2013.10.004] [Cited by in Crossref: 224] [Cited by in F6Publishing: 239] [Article Influence: 24.9] [Reference Citation Analysis]
62 Manjila SB, Baby JN, Bijin EN, Constantine I, Pramod K, Valsalakumari J. Novel gene delivery systems. Int J Pharm Investig 2013;3:1-7. [PMID: 23799200 DOI: 10.4103/2230-973X.108958] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
63 Reetz J, Genz B, Meier C, Kowtharapu BS, Timm F, Vollmar B, Herchenröder O, Abshagen K, Pützer BM. Development of Adenoviral Delivery Systems to Target Hepatic Stellate Cells In Vivo. PLoS One 2013;8:e67091. [PMID: 23825626 DOI: 10.1371/journal.pone.0067091] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
64 Xu Z, Qiu Q, Tian J, Smith JS, Conenello GM, Morita T, Byrnes AP. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med 2013;19:452-7. [PMID: 23524342 DOI: 10.1038/nm.3107] [Cited by in Crossref: 106] [Cited by in F6Publishing: 104] [Article Influence: 11.8] [Reference Citation Analysis]
65 Dreier B, Honegger A, Hess C, Nagy-Davidescu G, Mittl PR, Grütter MG, Belousova N, Mikheeva G, Krasnykh V, Plückthun A. Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters. Proc Natl Acad Sci U S A 2013;110:E869-77. [PMID: 23431166 DOI: 10.1073/pnas.1213653110] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
66 Chorny M, Fishbein I, Tengood JE, Adamo RF, Alferiev IS, Levy RJ. Site-specific gene delivery to stented arteries using magnetically guided zinc oleate-based nanoparticles loaded with adenoviral vectors. FASEB J 2013;27:2198-206. [PMID: 23407712 DOI: 10.1096/fj.12-224659] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
67 Alemany R. Viruses in cancer treatment. Clin Transl Oncol 2013;15:182-8. [DOI: 10.1007/s12094-012-0951-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
68 Bradshaw AC, Baker AH. Gene therapy for cardiovascular disease: perspectives and potential. Vascul Pharmacol 2013;58:174-81. [PMID: 23142171 DOI: 10.1016/j.vph.2012.10.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
69 Coughlan L, Vallath S, Gros A, Giménez-alejandre M, Van Rooijen N, Thomas GJ, Baker AH, Cascalló M, Alemany R, Hart IR. Combined Fiber Modifications Both to Target α v β 6 and Detarget the Coxsackievirus–Adenovirus Receptor Improve Virus Toxicity Profiles In Vivo but Fail to Improve Antitumoral Efficacy Relative to Adenovirus Serotype 5. Human Gene Therapy 2012;23:960-79. [DOI: 10.1089/hum.2011.218] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
70 Coughlan L, Bradshaw AC, Parker AL, Robinson H, White K, Custers J, Goudsmit J, Van Roijen N, Barouch DH, Nicklin SA, Baker AH. Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Mol Ther 2012;20:2268-81. [PMID: 22929662 DOI: 10.1038/mt.2012.162] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
71 Robertson KE, McDonald RA, Oldroyd KG, Nicklin SA, Baker AH. Prevention of coronary in-stent restenosis and vein graft failure: does vascular gene therapy have a role? Pharmacol Ther 2012;136:23-34. [PMID: 22796519 DOI: 10.1016/j.pharmthera.2012.07.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
72 Hiss DC, Fielding BC. Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy. Expert Opin Biol Ther 2012;12:1427-47. [PMID: 22788715 DOI: 10.1517/14712598.2012.707183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
73 Bradshaw AC, Coughlan L, Miller AM, Alba R, van Rooijen N, Nicklin SA, Baker AH. Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. J Control Release 2012;164:394-402. [PMID: 22626939 DOI: 10.1016/j.jconrel.2012.05.025] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
74 Duffy MR, Parker AL, Bradshaw AC, Baker AH. Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine 2012;7:271-88. [DOI: 10.2217/nnm.11.186] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
75 Wirth T. A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme. World J Exp Med 2011; 1(1): 10-16 [PMID: 24520527 DOI: 10.5493/wjem.v1.i1.10] [Cited by in CrossRef: 2] [Article Influence: 0.2] [Reference Citation Analysis]
76 Corjon S, Gonzalez G, Henning P, Grichine A, Lindholm L, Boulanger P, Fender P, Hong SS. Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interaction. PLoS One 2011;6:e18205. [PMID: 21637339 DOI: 10.1371/journal.pone.0018205] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]